Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer."
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
